The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCyanconnode Regulatory News (CYAN)

Share Price Information for Cyanconnode (CYAN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.30
Bid: 8.20
Ask: 8.40
Change: 0.00 (0.00%)
Spread: 0.20 (2.439%)
Open: 8.30
High: 8.30
Low: 8.30
Prev. Close: 8.30
CYAN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Oversubscribed Placing and Subscription

24 Jan 2023 08:00

RNS Number : 6670N
CyanConnode Holdings PLC
24 January 2023
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION.

This Announcement does not constitute a prospectus or offering memorandum or an offer in respect of any securities and is not intended to provide the basis for any investment decision in respect of CyanConnode Holdings plc or other evaluation of any securities of CyanConnode Holdings plc or any other entity and should not be considered as a recommendation that any investor should subscribe for or purchase any such securities.

This Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). In addition, market soundings (as defined in UK MAR) were taken in respect of certain of the matters contained in this Announcement, with the result that certain persons became aware of such inside information, as permitted by UK MAR. Upon the publication of this Announcement, this inside information is now considered to be in the public domain and such persons shall therefore cease to be in possession of inside information.

24 January 2023

CyanConnode Holdings plc

("CyanConnode" or the "Company")

Result of Oversubscribed Placing and Subscription

 

CyanConnode (AIM:CYAN.L), a world leader in narrowband radio frequency (RF) smart mesh networks, is pleased to announce that, further to its announcement at 5.11 p.m. on 23 January 2023, it has successfully completed a placing of new Ordinary Shares, by way of an accelerated bookbuild, which is now closed (the "Placing"), and a subscription (the "Subscription") of new Ordinary Shares (the Placing and the Subscription together being the "Fundraising"). The Placing was oversubscribed.

The Fundraising raised, in aggregate, £5.25 million (before expenses) through the placing of 30,882,352 new Ordinary Shares at an Issue Price of 17 pence per new Ordinary Share. The Issue Price is equal to the closing market price of 17 pence per existing Ordinary Share on 20 January 2023, being the last business day prior to the announcement of the Fundraising.

Directors' Dealings

Pursuant to the Fundraising and further to the Company's announcement on 23 January 2023, John Cronin, Heather Peacock, David Johns-Powell and Peter Tyler, each being a Director of the Company, have now participated a total of £115,000 in the Fundraising as follows:

 

 

Director

Role

Manner of participation

No. of existing Shares

% of existing Share Capital

Number of Shares subscribed for in Fundraise

No. of Shares held post-admission

% of enlarged Share Capital

John Cronin

Executive Chairman

Subscription

5,924,731

2.46%

294,117

6,218,848

2.29%

Heather Peacock

CFO and Company Secretary

Subscription

951,599

0.40%

117,647

1,069,246

0.39%

David Johns-Powell

Non-Executive Director

Subscription

16,474,503

6.85%

147,058

16,621,561

6.12%

Peter Tyler

Non-Executive Director

Subscription

2,489,004

1.03%

117,647

2,606,651

0.96%

 

John Cronin, Heather Peacock, David Johns-Powell and Peter Tyler as Directors of the Company, are accordingly classified as related parties under the AIM Rules for Companies and their participation in the Fundraising therefore constitutes a related party transaction pursuant to Rule 13 of the AIM Rules for Companies.

Accordingly, Chris Jones, being the independent director, considers, having consulted with Cenkos Securities Plc, the Company's Nominated Adviser, that the terms of the Directors' participation in the Fundraising is fair and reasonable insofar as Shareholders are concerned. 

Admission to trading on AIM

Application will be made to the London Stock Exchange for the admission of the new Ordinary Shares to trading on AIM ("Admission"). Further to the Company's announcement on 23 January 2023, it is now expected that Admission will become effective and dealings in the new Ordinary Shares will commence at 8.00 a.m. on or around 30 January 2023.

Total voting rights

Following the Admission, the Company will have 271,534,423 Ordinary Shares in issue. The Company holds no Ordinary Shares in Treasury. This figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Capitalised terms used but not otherwise defined in this announcement shall have the same meanings ascribed to such terms in the Company's announcement at 5.11 p.m. on 23 January 2023 unless otherwise specified.

John Cronin, Executive Chairman, CyanConnode, commented:

"We recently announced an order for c. 1 million units, taking orders won this financial year to 2.3 million units. This shows significant growth compared to the previous year where we had won orders for a total of 1.3 million units in all years prior to 31 March 2022. There are currently tenders out in India for more than 100 million units. The funds raised by this placing will allow us to maintain momentum and win some of the large opportunities being presented to us at this time. On behalf of the Board, I would like to thank all shareholders who have participated in this fundraising for their continued support."

Enquiries:

CyanConnode Holdings plc

 +44 (0) 1223 225 060

John Cronin, Executive Chairman

www.cyanconnode.com

 

 

Cenkos Securities plc (Nomad and Joint Broker)

 +44 (0) 20 7397 8900

Stephen Keys / Charlie Combe (Corporate Finance)

 

 

 

Zeus Capital Limited (Sole Bookrunner and Joint Broker)

+44 (0)20 3829 5000

Nick Cowles / Alexandra Campbell-Harris (Corporate Finance)

 

Simon Johnson (Corporate Broking)

 

 

Longspur Capital Limited (Placing Agent)

Nick Stamp / Akhil Shah (Corporate Finance)

Adam Robertson (Head of Distribution)

+44 (0)203 940 6601

 

IMPORTANT INFORMATION

This Announcement has been issued by, and is the sole responsibility of, the Company. No representation or warranty express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by Zeus Capital Limited or by any of its affiliates as to or in relation to, the accuracy or completeness of this Announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefore is expressly disclaimed.

This Announcement does not constitute, or form part of, a prospectus relating to the Company, nor does it constitute or contain any invitation or offer to any person, or any public offer, to subscribe for, purchase or otherwise acquire any shares in the Company or advise persons to do so in any jurisdiction, nor shall it, or any part of it (other than the Appendix in relation to Placees) form the basis of or be relied on in connection with any contract or as an inducement to enter into any contract or commitment with the Company. In particular, the new Ordinary Shares have not been, and will not be, registered under the Securities Act or qualified for sale under the laws of any state of the United States or under the applicable laws of any of Canada, Australia, the Republic of South Africa, or Japan and, subject to certain exceptions, may not be offered or sold in the United States or to, or for the account or benefit of, US persons (as such term is defined in Regulation S under the Securities Act) or to any national, resident or citizen of Canada, Australia, the Republic of South Africa or Japan.

The distribution or transmission of this Announcement and the offering of the new Ordinary Shares in certain jurisdictions may be restricted or prohibited by law or regulation. Persons distributing this Announcement must satisfy themselves that it is lawful to do so. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. No action has been taken by the Company or the Broker that would permit an offering of such shares or possession or distribution of this Announcement or any other offering or publicity material relating to such shares in any jurisdiction where action for that purpose is required. Persons into whose possession this Announcement comes are required by the Company and the Broker to inform themselves about, and to observe, such restrictions. In particular, this Announcement may not be distributed, directly or indirectly, in or into the United States, Canada, the Republic of South Africa, Australia or Japan. Overseas Shareholders and any person (including, without limitation, nominees and trustees), who have a contractual or other legal obligation to forward this document to a jurisdiction outside the UK should seek appropriate advice before taking any action.

This Announcement contains "forward-looking statements" which includes all statements other than statements of historical fact, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, or any statements preceded by, followed by or that include the words "targets", "believes", "expects", "aims", "intends", "will", "may", "anticipates", "would", "could", "indicative", "possible" or similar expressions or negatives thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this Announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based unless required to do so by applicable law or the AIM Rules for Companies.

No statement in this Announcement is intended to be a profit forecast and no statement in this Announcement should be interpreted to mean that earnings or losses per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings or losses per share of the Company.

Zeus Capital Limited ("Zeus"), which is authorised and regulated by the FCA in the United Kingdom, is acting as Broker to the Company in connection with the Placing. Zeus will not be responsible to any person other than the Company for providing the protections afforded to clients of Zeus or for providing advice to any other person in connection with the Placing or any acquisition of shares in the Company. Zeus is not making any representation or warranty, express or implied, as to the contents of this Announcement. Zeus has not authorised the contents of, or any part of, this Announcement, and no liability whatsoever is accepted by Zeus for the accuracy of any information or opinions contained in this Announcement or for the omission of any material information.

Cenkos Securities Plc ("Cenkos"), which is authorised and regulated by the FCA in the United Kingdom, is acting as Nominated Adviser to the Company in connection with the Fundraising. Cenkos has not authorised the contents of, or any part of, this Announcement, and no liability whatsoever is accepted by Cenkos for the accuracy of any information or opinions contained in this Announcement or for the omission of any material information. The responsibilities of Cenkos as the Company's Nominated Adviser under the AIM Rules for Companies and the AIM Rules for Nominated Advisers are owed solely to London Stock Exchange plc and are not owed to the Company or to any director or shareholder of the Company or any other person, in respect of its decision to acquire shares in the capital of the Company in reliance on any part of this Announcement, or otherwise.

The new Ordinary Shares will not be admitted to trading on any stock exchange other than the AIM market of the London Stock Exchange.

 

PDMR Notification Form

The notification below is made in accordance with the requirements of MAR.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

a) John Cronin

b) Heather Peacock

c) David Johns-Powell

d) Peter Tyler

 

2

Reason for the notification

a)

Position/status

a) Executive Chairman

b) CFO and Company Secretary

c) Non-Executive Director

d) Non-Executive Director

 

b)

Initial notification/Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

CyanConnode Holdings plc

b)

LEI

213800MDLW3GKKW5TT58

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 2 pence each

 

GB00BF93WP34

b)

Nature of the transaction

Participation in fundraising

c)

Price(s) and volume(s)

Price - 17 pence 

Volumes:

a) 294,117

b) 117,647

c) 147,058

d) 117,647

 

d)

Aggregated information

See 4c) above

e)

Date of the transaction

30 January 2023

f)

Place of the transaction

London Stock Exchange, AIM

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROIEAXFLASXDEEA
Date   Source Headline
18th Apr 20247:00 amRNSAppointment of Joint Broker
17th Apr 20241:56 pmRNSHolding(s) in Company
16th Apr 20247:00 amRNSTrading Update
15th Apr 20247:00 amRNSOrder For A New Deployment In India
12th Apr 20247:00 amRNSMiddle East Energy Leadership Summit 2024
15th Jan 20247:00 amRNSAppointment of Non-Executive Director
11th Jan 20247:00 amRNSOrder For One Million Omnimesh Modules
27th Dec 20234:18 pmRNSDirector Dealing
19th Dec 20237:00 amRNSInterim Results
6th Dec 20231:32 pmRNSChange of Registered Office
1st Dec 20234:18 pmRNSHolding(s) in Company
21st Nov 20232:31 pmRNSHolding(s) in Company
20th Nov 20236:14 pmRNSIssue of Share Options – Correction
20th Nov 20237:00 amRNSNamed as One of the Fastest Growing Companies
17th Nov 20233:45 pmRNSDirector Option Grants
17th Nov 20238:30 amRNSHolding(s) in Company
16th Nov 202312:48 pmRNSHolding(s) in Company
15th Nov 20237:00 amRNSRanked 2nd Fastest-Growing UK Company in India
13th Nov 20236:11 pmRNSPlacing and Subscription – update
9th Nov 20238:02 amRNSResult of Oversubscribed Placing and Subscription
8th Nov 20235:24 pmRNSProposed Placing and Subscription to Raise c.£2.5m
31st Oct 20237:15 amRNSContract in the Middle East and North Africa
10th Oct 20237:00 amRNSOrder for 300,000 Omnimesh Modules
5th Oct 20237:00 amRNSTrading Update
24th Aug 202312:18 pmRNSResult of AGM
17th Aug 20231:00 pmRNSHolding(s) in Company
15th Aug 20237:00 amRNS2023 Annual General Meeting
4th Aug 20235:34 pmRNSDirector Dealing
2nd Aug 20237:00 amRNSOrder for 300,000 Omnimesh Modules
26th Jul 20235:34 pmRNSCorrection: Final Results
26th Jul 20237:00 amRNSFinal Results
25th Jul 20237:00 amRNSNotice of Results & Investor Presentation
6th Jul 20237:00 amRNSTrading Update
22nd Jun 20237:00 amRNSCyanConnode India is a Start-Up 50 Trailblazer
25th May 20238:10 amRNSOrder for 600,000 Omnimesh Modules
9th May 20233:45 pmRNSHolding(s) in Company
17th Apr 20237:00 amRNSInterview with MD & CEO for CyanConnode India
3rd Apr 20237:00 amRNSCyanConnode and Alfanar Sign MOU for AMI projects
21st Mar 20237:15 amRNSHardman Research - Acceleration and revenue uplift
13th Mar 20237:00 amRNSCyanConnode Banking Arrangements
7th Mar 20237:00 amRNSCollaboration with Silicon Laboratories
6th Mar 20237:00 amRNSAppointment of Nominated and Financial Adviser
6th Feb 20238:51 amRNSStrategic Framework Agreement - Replacement
6th Feb 20238:21 amRNSStrategic Framework Agreement
6th Feb 20237:00 amRNSStrategic Framework Agreement
31st Jan 20237:00 amRNSHolding(s) in Company
24th Jan 20238:00 amRNSResult of Oversubscribed Placing and Subscription
23rd Jan 20235:11 pmRNSProposed Placing and Subscription
19th Jan 20237:00 amRNSChange of Adviser
4th Jan 20237:00 amRNSOrder From New Partner

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.